Influence of L-thyroxine administration on poor-platelet plasma VEGF concentrations in patients with induced short-term hypothyroidism, monitored for thyroid carcinoma.
Angiogenesis is a process of new blood vessel development from pre-existing vasculature. It is a crucial process in normal physiology, as well as in several pathological conditions. The vascular endothelial growth factor (VEGF) represents a family of specific endothelial cell mitogens, involved in normal angiogenesis and in tumour development. The aim of the present study was to estimate the influence of L-thyroxine (L-T4) administration on poor-platelet plasma (P-PP) VEGF concentrations in patients with induced short-term hypothyroidism, monitored for differentiated thyroid carcinoma. In the present study, P-PP concentrations of VEGF, thyroglobulin, thyrotropin and free thyroid hormones were investigated in a population of 24 hypothyroid patients, who were withdrawn from L-T4 treatment for 5 weeks and studied before and after 2 months of L-T4 therapy. Only healthy female patients with no evidence of metastasis in whole body scintigraphy were included in the study. They were then compared with 20 healthy control subjects, matched for age, sex and body mass index (BMI). The patients had significantly lower plasma VEGF concentrations before treatment with L-T4 than after administration of that hormone. There was no significant difference in plasma VEGF levels, either between the patients treated with L-T4, and the controls, or between the patients untreated with L-T4, and the controls. Even short-time changes in thyrometabolic profile exert an important influence on P-PP VEGF concentrations, even if there is no thyroid tissue.
Dedecjus
Marek
M
Department of Endocrine Surgery, Medical University of Lodz, Polish Mother's Memorial Hospital-Research Institute.
Kołomecki
Krzysztof
K
Brzeziński
Jan
J
Adamczewski
Zbigniew
Z
Tazbir
Józef
J
Lewiński
Andrzej
A
D001792:Blood Platelets / Q000378:metabolism; D002277:Carcinoma / Q000150:complications / Q000175:diagnosis*; D016022:Case-Control Studies; D002469:Cell Separation; D005260:Female; D006801:Humans; D007037:Hypothyroidism / Q000209:etiology*; D008297:Male; D013960:Thyroid Function Tests; D013964:Thyroid Neoplasms / Q000150:complications / Q000175:diagnosis*; D013965:Thyroidectomy / Q000009:adverse effects; D013974:Thyroxine / Q000008:administration & dosage / Q000494:pharmacology*; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*; D028761:Withholding Treatment
D042461:Vascular Endothelial Growth Factor A; D013974:Thyroxine